BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/2/2021 12:29:13 PM | Browse: 496 | Download: 654
 |
Received |
|
2020-12-07 01:49 |
|
Peer-Review Started |
|
2020-12-07 01:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-30 19:51 |
|
Revised |
|
2021-01-10 17:29 |
|
Second Decision |
|
2021-01-27 08:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-01-28 05:06 |
|
Articles in Press |
|
2021-01-28 05:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-02-07 08:27 |
|
Typeset the Manuscript |
|
2021-03-15 02:16 |
|
Publish the Manuscript Online |
|
2021-04-02 12:29 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xu-Yan Hu, Yu-Cheng Fei, Wen-Chao Zhou, Jin-Miao Zhu and Dong-Lai Lv |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation Project of Anhui Province |
1808085MH267 |
| Key Research and Development Project of Anhui Province |
202004a07020020 |
|
| Corresponding Author |
Dong-Lai Lv, BPhty, DVSc, MD, Chief Doctor, Doctor, Department of Clinical Oncology, 901 Hospital of Joint Logistic Support Force, No. 424 West Changjiang Road, Shushan District, Hefei 230031, Anhui Province, China. lvxunhuan@163.com |
| Key Words |
Osimertinib; Retreatment; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Non-small cell lung cancer; Case report |
| Core Tip |
Osimertinib is the first-line recommended treatment for adult patients with epidermal growth factor receptor mutation positive advanced or metastatic non-small cell lung cancer. Once drug-resistance occurs in osimertinib, the standard of care is to discontinue the tyrosine kinase inhibitor. To the best of our knowledge, this is the first report of successful re-challenge and tri-challenge with osimertinib administered via multiple re-sensitization chemotherapy protocols. This case provides a useful reference for prolonging the efficacy of osimertinib. |
| Publish Date |
2021-04-02 12:29 |
| Citation |
Hu XY, Fei YC, Zhou WC, Zhu JM, Lv DL. Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(11): 2627-2633 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i11/2627.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i11.2627 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
